Source: International Congress 2019 – Interstitial lung disease registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Kalafatis (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), G. Ferrara (Stockholm, Sweden), M. Sköld (Stockholm, Sweden). Autoantibodies in patients with idiopathic pulmonary fibrosis. 4713

Member's Comments

No comment yet.

Related content which might interest you: Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Registry of idiopathic pulmonary fibrosis patients Source: International Congress 2016 – Russia Session Year: 2016 Clinical features of patients with idiopathic pulmonary upper lobe-dominant fibrosis Source: International Congress 2016 – Orphan diseases I Year: 2016 Pulmonary fibrosis: “idiopathic” is not “cryptogenic” Source: Eur Respir J, 53 (3) 1802314; 10.1183/13993003.02314-2018 Year: 2019 Pulmonary fibrosis: “idiopathic” is not “cryptogenic” Source: Eur Respir J, 53 (3) 1900400; 10.1183/13993003.00400-2019 Year: 2019 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip Source: ERS Lung Science Conference 2021 Year: 2021 Immunogenetic background of children´s idiopathic interstitial pneumonias and adult idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Approach to diagnosis of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Towards a better diagnosis of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 108-113 Year: 2011